LDL subfractions and atherogenicity: An hypothesis from the University of Glasgow

Current Medical Research and Opinion

Volumn 13, Issue 7, 1996, Pages 379-390

  Packard, C J ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Atherogenesis; Cholesterol ester transfer protein; Fibrates; LDL subfractions; Triglycerides

Indexed keywords

FENOFIBRATE; FIBRIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; PLASMIN; TRIACYLGLYCEROL;

ARTERY WALL; ARTICLE; ATHEROGENESIS; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG EFFICACY; ENDOTHELIUM CELL; FIBRIN DEPOSITION; HEART INFARCTION; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL; CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; PROCETOFEN; RISK FACTORS; TRIGLYCERIDES;

EID: 0029548452     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999609111557     Document Type: Article

References (19)

1. Hokanson, J., and Austin M., (1993). Plasma triglycerides and coronary risk. A meta-analysis. Circulation, 88, 1-510.
2. Austin, M.A., Breslow, J.L., Hennekens, C.H., et al., (1988). Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA, 260, 1917-21.
3. Tall, A.R., (1995). Plasma cholesterol ester transfer protein and high density lipoproteins: new insights from molecular genetic studies. J Intern Med., 237, 5-12.
4. Tato, F., Vega, G.L., Tall, A.R., et al., (1995). Relation between cholesterol transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolaemia and combined hyperlipidaemia. Arterioscler Thromb Vasc Biol., 15, 112-20.
5. Watts, G.F., Lewis, B., Brunt, J.N.H., et al., (1992). Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet, 339, 563-9.
6. Blankenhorn, D.H., Azen, S.P., Crawford, D.W., et al., (1991). Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation, 83, 438-47.
7. Scandinavian Simvastatin Survival Study Group, (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet, 344, 1383-9.
8. Griffin, B.A., Freeman, D.J., Tait, G.W., et al., (1994). Role of plasma triglyceride in the regulation of plasma low density lipids to coronary heart disease risk. Atherosclerosis, 106, 241-53.
9. Shepherd, J., Caslake, M.J., Lorimer, A.R., et al., (1985). Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis, 5, 162-8.
10. Caslake, M.J., Packard, C.J., Gaw, A., et al., (1993). Fenofibrate and metabolic heterogeneity in hypercholesterolaemia. Arterioscler Thromb., 13, 702-11.
11. Dinchuk, J., Hart, J., Gonzalez, G., et al., (1995). Remodelling of lipoproteins in transgenic mice expressing human cholesterol ester transfer protein. Biochim Biophys Acta., 1255, 301-10.
12. Dullaart, R.P., Hoogenberg, K., Dikkeschei, B.D., et al., (1994). Higher plasma lipid transfer protein activities and unfavorable lipoprotein changes in cigarette-smoking men. Arterioscler Throm., 14, 1581-5.
13. Freeman, D.J., Griffin, B.A., Holmes, A.P., et al., (1994). Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity. Arterioscler Thromb., 14, 336-44.
14. Kotze, M.J., Davis, H.J., Bissbot, S., et al., (1993). Intrafamilial variability in the clinical expression of familial hypercholesterolaemia: importance of risk factor determination for genetic counselling. Clinical Genetics, 43, 295-99.
15. Cheung, M.C., Austin, M.A., Moulin, P., et al., (1993). Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolaemia. Atherosclerosis, 102, 107-19.
16. Cigolini, M., Targher, G., and Seidell, J.C., (1994). Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis, 106, 139-47.
17. Asplund-Carlson, A., Hamsten, A., Wiman, B., et al., (1993). Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologica, 13, 1865-73.
18. Stiko-Rahm, A., Wiman, B., Hamsten, A., et al., (1990). Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoproteins. Arteriosclerosis, 9, 134-9.
19. Mussoni, L., Mannuci, L., Sirtori, M., et al., (1992). Hypertriglyceridaemia and regulation of fibrinolytic activity. Arterioscler Thromb., 12, 19-23.